Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aspirin 162 mg Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aspirin Dose and Atherosclerosis in Patients With Heart Disease

NCT00272337
View directory record Official record
Conditions
Cardiovascular Diseases, Atherosclerosis, Myocardial Infarction
Interventions
Aspirin
Drug
Lead sponsor
Florida Atlantic University
Other
Eligibility
40 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
2
States / cities
Atlantis, Florida • Tamarac, Florida
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Sep 26, 2026, 5:11 AM EDT
Terminated Phase 3 Interventional Results available

Aspirin for Treatment of Multiple Sclerosis-Related Fatigue

NCT00467584
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue
Interventions
High Dose Aspirin (1300 mg/day), Low Dose Aspirin (162 mg/day), Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 26, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia

NCT03893630
View directory record Official record
Conditions
Pre-Eclampsia
Interventions
Acetylsalicylic Acid 81 mg, Acetylsalicylic Acid 162 mg, Control
Drug · Other
Lead sponsor
John O'Brien, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 26, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Results available

Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?

NCT01040819
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pioglitazone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 26, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)

NCT01510327
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Loveland, Colorado • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 26, 2026, 5:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin

NCT04328883
View directory record Official record
Conditions
Platelet Aggregation Inhibitors
Interventions
Aspirin
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 26, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions

NCT00823212
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 26, 2026, 5:11 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

162 mg of Aspirin for Prevention of Preeclampsia

NCT05221164
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin 162 mg
Drug
Lead sponsor
Methodist Medical Center of Illinois
Other
Eligibility
Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Sep 26, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome

NCT00272311
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Syndrome X, Atherosclerosis
Interventions
Aspirin
Drug
Lead sponsor
Florida Atlantic University
Other
Eligibility
40 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 26, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

NCT02671461
View directory record Official record
Conditions
Thrombosis
Interventions
BMS-986141, Aspirin, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
27
States / cities
Phoenix, Arizona • Newport Beach, California • Newark, Delaware + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 26, 2026, 5:11 AM EDT
Completed Phase 4 Interventional

Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement

NCT02810704
View directory record Official record
Conditions
Pulmonary Embolism, Venous Thrombosis
Interventions
Enteric Coated Aspirin, Warfarin, Rivaroxaban
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
18,883 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
30
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 26, 2026, 5:11 AM EDT
Recruiting Phase 3 Interventional

APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia

NCT06408181
View directory record Official record
Conditions
Pre-Eclampsia, Pregnancy Loss
Interventions
Aspirin 162 mg, Aspirin 81mg
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 26, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Results available

Aspirin Dosing in Diabetic Patients

NCT01201785
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Coronary Artery Disease
Interventions
Aspirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Sep 26, 2026, 5:11 AM EDT
Recruiting Phase 3 Interventional

Trial to Determine Effective Aspirin Dose in COPD

NCT05265299
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Aspirin 81mg, Aspirin 162 mg, Aspirin 325mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 26, 2026, 5:11 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Aspirin (ASA) Therapy and Preeclampsia Prevention

NCT04158830
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin 81 mg Enteric Coated Tab - 1 tablet, Aspirin 81 mg Enteric Coated Tab - 2 tablets
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
14 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 26, 2026, 5:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Healthy Adults.

NCT05625334
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASA, non-enteric-coated chewable aspirin
Drug
Lead sponsor
Vectura, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 26, 2026, 5:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparative Effects of Aspirin and NHP-544C

NCT02189122
View directory record Official record
Conditions
Healthy
Interventions
Bradykinin, Aspirin 81 mg, Aspirin 162 mg, NHP544-C 81 mg, NHP544C 162 mg, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 26, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)

NCT01500434
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
21
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 26, 2026, 5:11 AM EDT
Terminated Phase 4 Interventional Results available

Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study

NCT01452152
View directory record Official record
Conditions
Cardiovascular Diseases, Acute Coronary Syndrome
Interventions
clopidogrel, prasugrel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years to 74 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Newark, Delaware • Baltimore, Maryland • Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 26, 2026, 5:11 AM EDT
Recruiting Phase 4 Interventional

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

NCT06468202
View directory record Official record
Conditions
Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Interventions
Aspirin 81 mg, Aspirin 162 mg
Drug
Lead sponsor
Ohio State University
Other
Eligibility
14 Years to 35 Years · Female only
Enrollment
10,742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 26, 2026, 5:11 AM EDT
Terminated Phase 1 Interventional

Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function

NCT05625347
View directory record Official record
Conditions
Obstructive Pulmonary Function, Restrictive Pulmonary Function
Interventions
single dose (100 mg) of ASA, single dose (162 mg) of non-enteric-coated chewable aspirin tablets
Drug
Lead sponsor
Vectura, Inc.
Industry
Eligibility
40 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
4
States / cities
Orlando, Florida • Winter Park, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 26, 2026, 5:11 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients

NCT05514847
View directory record Official record
Conditions
Preeclampsia, Pregnancy Related
Interventions
Aspirin 81Mg Ec Tab, Aspirin 162Mg Ec Tab
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 26, 2026, 5:11 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida

NCT03961360
View directory record Official record
Conditions
Pre-Eclampsia, Hypertension in Pregnancy, Obesity
Interventions
Aspirin 81 mg, Aspirin 162 mg
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 26, 2026, 5:11 AM EDT